[ad_1]
The accelerated tests of the company Advent-Irbm in Pomezia will begin with 550 healthy volunteers. If the phase 1 clinical trial had passed successfully, the vaccine could be available as early as September
by Francesca Cerati
2 ‘reading
As the coronavirus progresses, certainties and consolidated scientific procedures over the years are falling one after the other. Rigid drug and vaccine testing times have already faltered for a couple of months.
The proof is that on Monday the 13th, after the American Modern, also the Italian Advent-Irbm of Pomezia in association with the Jenner Institute of the University of Oxford, announced that accelerated human tests of its vaccine will begin at the end of April. .
“Based on data acquired in recent weeks, the first batch of the vaccine will leave Pomezia for England, where accelerated tests will begin on 550 healthy volunteers – specified Pietro Di Lorenzo, CEO of Advent, the Cnccs Consortium and Irbm Spa – It was decided to go directly to the human clinical trial phase, as we believe that the non-toxicity and efficacy of the vaccine were sufficiently tested based on laboratory results, which were particularly effective. “
Not only that, if the phase 1 clinical trial (which provides an initial evaluation of the drug’s safety and tolerability) was successfully approved, “the vaccine is expected to be usable as early as September – Di Lorenzo continues – to vaccinate staff of health and the forces of order in compassionate use ».
Di Lorenzo also announces that: “Negotiation of a major loan with a group of international investors and several governments interested in further accelerating the development and industrial production of the vaccine is now in the final phase.”
